Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24711906 | 0.87 | FOLH1 (0.51) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL29291292 | 0.83 | FOLH1 (0.47) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL24376227 | 0.81 | SLC6A5 (0.52) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL1443498 | 0.81 | FOLH1 (0.56) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL1443500 | 0.81 | FOLH1 (0.56) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL3389707 | 0.80 | SLC6A5 (0.54) | FOLH1SLC6A5ACE | |
| SCHEMBL23451044 | 0.80 | FOLH1 (0.51) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL5419504 | 0.80 | FOLH1 (0.51) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL7107134 | 0.79 | FOLH1 (0.54) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL8576386 | 0.79 | FOLH1 (0.54) | FOLH1GSRRNPEPMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114624362-A | Kit for detecting advanced glycosylation end products in serum and application thereof | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2022-06-14 | — | — | CN | claimed |
| WO-2024054682-A2 | ULTRALOW MOLECULAR WEIGHT HEPARIN | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-03-14 | — | — | WO | disclosed |
| US-11369498-B2 | Stent and stent delivery system with improved deliverability | MT Acquisition Holdings LLC (US) | 2022-06-28 | — | — | US | disclosed |
| CN-114624362-A | Kit for detecting advanced glycosylation end products in serum and application thereof | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2022-06-14 | — | — | CN | disclosed |
| US-10813911-B2 | Methods of treating and/or preventing chronic obstructive pulmonary disease | UNIV BORDEAUX (FR) | 2020-10-27 | — | — | US | disclosed |
| EP-3613435-A1 | CHEMOKINE RECEPTOR CXCR4 INHIBITORS FOR TREATING AND/OR PREVENTING CHRONIC OBSTRUCTIVE PULMONARY DISEASE | UNIVERSITE DE BORDEAUX (FR) | 2020-02-26 | — | — | EP | disclosed |
| EP-3050574-B1 | Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease | UNIV BORDEAUX (FR) | 2019-10-09 | — | — | EP | disclosed |
| US-20180271831-A1 | NEW COMPOSITIONS AND METHODS OF TREATING AND/OR PREVENTING CHRONIC OBSTRUCTIVE PULMONARY DISEASE | UNIV BORDEAUX (FR) | 2018-09-27 | — | — | US | disclosed |
| EP-2531140-B1 | STENT AND STENT DELIVERY SYSTEM WITH IMPROVED DELIVERABILITY | MICELL TECHNOLOGIES INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170189586-A1 | BIOABSORBABLE COATING FOR BIOABSORBABLE STENT | ABBOTT CARDIOVASCULAR SYSTEMS INC (US) | 2017-07-06 | — | — | US | disclosed |
| US-20110190864-A1 | STENT AND STENT DELIVERY SYSTEM WITH IMPROVED DELIVERABILITY | MICELL TECHNOLOGIES, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-7763271-B1 | Polymeric micelle-based local delivery methods and devices | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20100047319-A1 | Biodegradable Poly(Ester-Amide) And Poly(Amide) Coatings For Implantable Medical Devices With Enhanced Bioabsorption Times | ABBOTT CARDIOVASCULAR SYSTEMS INC. | 2010-02-25 | — | — | US | disclosed |
| US-20090258029-A1 | Heparin Prodrugs and Drug Delivery Stents Formed Therefrom | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090258054-A1 | Heparin Prodrugs and Drug Delivery Stents Formed Therefrom | ABBOTTE CARDIOVASCULAR SYSTEMS INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090258047-A1 | Heparin Prodrugs and Drug Delivery Stents Formed Therefrom | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090258055-A1 | Heparin Prodrugs and Drug Delivery Stents Formed Therefrom | ABBOTTE CARDIOVASCULAR SYSTEMS INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-7563780-B1 | Heparin prodrugs and drug delivery stents formed therefrom | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7396541-B2 | Heparin prodrugs and drug delivery stents formed therefrom | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20060014720-A1 | Heparin prodrugs and drug delivery stents formed therefrom | ADVANCED CARDIOVASCULAR SYSTEMS, INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014720-A1 | Heparin prodrugs and drug delivery stents formed therefrom | PLAUR, HDGF, AXL | FOLH1 176/4885GSR 4020/4885RNPEP 1795/4885 |
| US-20100047319-A1 | Biodegradable Poly(Ester-Amide) And Poly(Amide) Coatings For Implantable Medical Devices With Enhanced Bioabsorption Times | SLC10A2, SI, PAM | FOLH1 1198/4885GSR 4789/4885RNPEP 388/4885 |
| US-20090258054-A1 | Heparin Prodrugs and Drug Delivery Stents Formed Therefrom | PLAUR, HDGF, AXL | FOLH1 176/4885GSR 4020/4885RNPEP 1795/4885 |
| US-20090258055-A1 | Heparin Prodrugs and Drug Delivery Stents Formed Therefrom | PLAUR, HDGF, AXL | FOLH1 176/4885GSR 4020/4885RNPEP 1795/4885 |
| US-20090258029-A1 | Heparin Prodrugs and Drug Delivery Stents Formed Therefrom | PLAUR, HDGF, AXL | FOLH1 176/4885GSR 4020/4885RNPEP 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.